The purpose of this study is to test the hypothesis that autologous dendritic cells pulsed with autologous crude tumor cell lysates or melanoma peptides can be prepared and injected into melanoma patients along with IL-2 without significant toxicity. We wish to determine if treatment with melanoma tumor antigen pulsed autologous dendritic cells will increase tumor specific cytotoxic T-cell responses and induce positive skin test responses to tumor antigens. Patients eligible will be ones with metastatic disease to regional lymph nodes and can prove to be tyrosinase and/or gp100 positive. Patients are distributed into three groups. Group A will include patients without adequate tumor for preparation of tumor lysate. These patients will be tested for eligibility for the peptide pulsed autologous dendritic cell protocol, and will be included in this protocol if their tumor expresses gp100 protein and tyrosinase, and they type for HLA-A1,-A2,-A3. Group B will include patients with adequate tumor for lysate but who are not eligible for the peptide pulsed protocol because they are not HLA-A1, A2, or A3. They will be eligible for the lysate pulsed autologous dendritic cell protocol. GroupC will include patients with adequate tumor for lysate which expresses gp100 and/or tyrosinase and who type for HLA-A1, -A2, or -A3. They are eligible for randomization to receive either the peptide pulsed protocol or tumor lysate. We plan to study 100 patients for this study and at the present time there are 45 patients that have signed the consent form, have had their surgery and are approaching treatment or have already been treated. This trial is also being done at the University of Virginia with Dr. Craig Slingluff. To date they have placed 5 patients on study. We have not seen any significant adverse events. There has been skin peeling, itching and redness at time of treatment that is of short duration as well as some taste alteration. These side effects are considered to be much less than the ones that are associated with High dose Interferon and chemotherapy. There have been 5 recurrences since the protocol was started which now is over 1 year and of these 5 patients all are still alive. Our projected date for completion of this study is May of 2000. Significance: Patients with melanoma who have one lymph node involved have a 60% chance of dying secondary to melanoma and this progresses to greater that 90% if they have four or more lymph nodes involved. To date the treatments available are other phase I studies using some type of vaccine, high dose interferon, high dose IL-2, chemotherapy, surgery alone, or for local control radiation therapy. New therapies are needed for this disease.
| Askie, Lisa M; Darlow, Brian A; Finer, Neil et al. (2018) Association Between Oxygen Saturation Targeting and Death or Disability in Extremely Preterm Infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration. JAMA 319:2190-2201 |
| Srinivasan, Lakshmi; Page, Grier; Kirpalani, Haresh et al. (2017) Genome-wide association study of sepsis in extremely premature infants. Arch Dis Child Fetal Neonatal Ed 102:F439-F445 |
| Denson, Lee A; McDonald, Scott A; Das, Abhik et al. (2017) Early Elevation in Interleukin-6 is Associated with Reduced Growth in Extremely Low Birth Weight Infants. Am J Perinatol 34:240-247 |
| James, Jennifer; Munson, David; DeMauro, Sara B et al. (2017) Outcomes of Preterm Infants following Discussions about Withdrawal or Withholding of Life Support. J Pediatr 190:118-123.e4 |
| Younge, Noelle; Goldstein, Ricki F; Bann, Carla M et al. (2017) Survival and Neurodevelopmental Outcomes among Periviable Infants. N Engl J Med 376:617-628 |
| Archer, Stephanie Wilson; Carlo, Waldemar A; Truog, William E et al. (2016) Improving publication rates in a collaborative clinical trials research network. Semin Perinatol 40:410-417 |
| Ahmed, Zuhayer; Prasad, Indrajit; Rahman, Hafizur et al. (2016) A Male with Extreme Subcutaneous Insulin Resistance: A Case Report. Rom J Diabetes Nutr Metab Dis 23:209-213 |
| Phelps, Dale L; Ward, Robert M; Williams, Rick L et al. (2016) Safety and pharmacokinetics of multiple dose myo-inositol in preterm infants. Pediatr Res 80:209-17 |
| Barroso, Julie; Leserman, Jane; Harmon, James L et al. (2015) Fatigue in HIV-Infected People: A Three-Year Observational Study. J Pain Symptom Manage 50:69-79 |
| Stafford-Smith, Mark; Li, Yi-Ju; Mathew, Joseph P et al. (2015) Genome-wide association study of acute kidney injury after coronary bypass graft surgery identifies susceptibility loci. Kidney Int 88:823-32 |
Showing the most recent 10 out of 128 publications
